Adaptive Biotechnologies 2024年第四季度GAAP每股亏损$(0.23)优于预期$(0.26),销售额$47.459百万超过预期$46.034百万

财报速递02-11
Adaptive Biotechnologies (NASDAQ:ADPT) 报告季度每股亏损$(0.23),优于分析师共识预期的$(0.26),超出11.54%。公司报告季度销售额$47.459百万,超过分析师共识预期的$46.034百万,超出3.09%。相比去年同期的$45.784百万,销售额增长了3.66%。

以上内容来自Benzinga Earnings专栏,原文如下:

Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.26) by 11.54 percent. The company reported quarterly sales of $47.459 million which beat the analyst consensus estimate of $46.034 million by 3.09 percent. This is a 3.66 percent increase over sales of $45.784 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法